Page 286 - 2021_02-Haematologica-web

600
Letters to the Editor
py only and supportive care only, results in the best out- come in elderly patients judged eligible to receive such treatment, with a 2-year OS of approximately 50%. The challenge remains to balance the benefits and risks of intensive chemotherapy in this patient group. Therefore, future prospective intervention studies are needed to assess which elderly patients can benefit from intensive chemotherapy or less intensive approaches.
Matthijs van der Meulen,1,2 Jacoline E.C. Bromberg,1 Marcel Nijland,3 Otto Visser,4 Jeanette K. Doorduijn5 and Avinash G. Dinmohamed5,6,7
1Department of Neuro-Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam; 2Department of Neurology, Medical Spectrum Twente, Enschede; 3Department of Hematology, University Medical Center Groningen, Groningen; 4Department of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht; 5Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam; 6Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht and 7Department of Public Health, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands
Correspondence:
M. VAN DER MEULEN - m.vandermeulen.2@erasmusmc.nl
doi:10.3324/haematol.2020.247536
Disclosures: no conflicts of interests to disclose.
Contributions: JECB and AGD designed the study; AGD analyzed the data; OV collected the data; MvdM wrote the manuscript with contributions from JECB, MN, OV, JKD and AGD; and all authors interpreted the data, and read, commented on, and approved the final version of the manuscript.
Acknowledgments: the authors would like to thank the registration clerks of the Netherlands Cancer Registry (NCR) for their dedicated data collection. The nationwide population-based NCR is maintained and hosted by the Netherlands Comprehensive Cancer Organisation (IKNL).
References
1.van der Meulen M, Dinmohamed AG, Visser O, Doorduijn JK, Bromberg JEC. Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on inci- dence, primary treatment and survival in the Netherlands, 1989-
2015. Leukemia. 2017;31(8):1822-1825.
2. Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radio-
therapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunothera- py in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510-e523.
3. Bromberg JEC, Issa S, Bakunina K, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a ran- domised, open-label, phase 3 intergroup study. Lancet Oncol. 2019; 20(2):216-228.
4. Omuro A, Chinot O, Taillandier L, et al. Methotrexate and temo- zolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015;2(6):e251-e259.
5. Fritsch K, Kasenda B, Schorb E, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017;31(4):846-852.
6. Siegal T, Bairey O. Primary CNS lymphoma in the elderly: the chal- lenge. Acta Haematol. 2019;141(3):138-145.
7. Mendez JS, Ostrom QT, Gittleman H, et al. The elderly left behind- changes in survival trends of primary central nervous system lym- phoma over the past 4 decades. Neuro Oncol. 2018;20(5):687-694.
8. Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA, Jager JJ. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol. 1993;22(3):369-376.
9. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for pri- mary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21(2):266-272.
10. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24(36):5711-5715.
11. Kasenda B, Ferreri AJ, Marturano E, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Ann Oncol. 2015;26(7):1305-1313.
12. Korfel A, Thiel E, Martus P, et al. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology. 2015;84(12):1242-1248.
13. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G- PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036-1047.
14. Schmitt AM, Herbrand AK, Fox CP, et al. Rituximab in primary cen- tral nervous system lymphoma- a systematic review and meta- analysis. Hematol Oncol. 2019;37(5):548-557.
15. Neuhauser M, Roetzer T, Oberndorfer S, et al. Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study. Acta Oncol. 2019;58(7):967-976.
haematologica | 2021; 106(2)